Alleviation of Erythromelalgia With Venlafaxine

DiCaudo, David J.; Kelley, Lee Ann

doi:10.1001/archderm.140.5.621

Cited by 13 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maintenance dosage is 75 to 225 mg/d in two to three divided doses (once a day for extended-release formulation). DiCaudo and Kelley [63] reported alleviation of erythromelalgia with venlafaxine. Dosage adjustments are required in renal impairment and liver disease.…”

Section: Serotonin Reuptake Inhibitors: Venlafaxine Sertralinementioning

confidence: 99%

Erythromelalgia

Davis

Rooke²

2006

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

No treatment is consistently effective in the management of patients with erythromelalgia. There is a dearth of adequate studies examining the response of erythromelalgia to treatment. Most recommendations are suggested based on case reports, small case series, and anecdotal reports. The management of erythromelalgia is difficult and frequently involves a multidisciplinary approach. An approach to management of individuals with erythromelalgia includes patient education, learning to avoid episodes, relieving discomfort of the episodes, controlling secondary and underlying factors, and use of drugs used to control erythromelalgia.

show abstract

Section: Serotonin Reuptake Inhibitors: Venlafaxine Sertralinementioning

confidence: 99%

Erythromelalgia

Davis

Rooke²

2006

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

show abstract

“…Other drugs indicated are pregabalin, starting at a dose of 75 mg.day −1 , increasing every three days up to 300 mg twice, 21 amitriptyline (starting with 12.5–25 mg at night, increased to 100 mg at night), and venlafaxine (starting at 37.5–75 mg in the morning), increasing to 225 mg.day −1 twice daily. 22 Other less effective drugs include selective serotonin reuptake inhibitors (sertraline), sodium channel blockers (oral mexiletine and venous lidocaine), 23 and anticonvulsant drugs (carbamazepine), 24 outpatient treatment proposed to the patient in this case.…”

Section: Discussionmentioning

confidence: 99%

Pain management in children with erythromelalgia: case report

Bortoli

Sakata

2018

Brazilian Journal of Anesthesiology (English Edition)

View full text Add to dashboard Cite

“…In 3 patients, venlafaxine has provided some relief from symptoms of by acting both on sympathetic fibers by inhibiting the reuptake of noradrenaline, as well as on hormonal vascular control by inhibiting the reuptake of serotonin [43][44][45]. As this medication is approved to treat major depression, which is a common comorbidity among these patients, it is likely to prove useful for both diseases.…”

Section: Discussionmentioning

confidence: 99%

Clinical Challenges in Primary Erythromelalgia: A Real-Life Experience from a Single Center and a Diagnostic-Therapeutic Flow-Chart Proposal

Michelerio

Tomasini

Arbustini

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Primary erythromelalgia (EM) is a rare clinical syndrome characterized by recurrent erythema, burning pain and warmth of the extremities. The symptoms greatly compromise the patients' quality of life leading to severe disability. SCN9A mutations can be the cause of the disease. Dermatologists are often the specialists these patients turn to for assistance. Objectives: To describe the demographic and clinical characteristics of patients with primary EM, to assess the presence and mutation types in the SCN9A gene, to evaluate the effectiveness of several therapeutic approaches, and to propose a diagnostic algorithm with therapeutic implications. Methods: A monocentric retrospective study using the database of patients with a discharge diagnosis of primary EM of our Center. Demographic, clinical, instrumental and laboratory data of patients were reviewed. Results: Eleven female patients (age range 16 to 57) were selected. All patients were affected in both the lower and upper extremities. Follow-up ranged from 2 to 9 years. Four patients had four different heterozygous variants of the SCN9A gene. Two patients, although genetically negative, had a suggestive family history. A variety of medications were tried in all our patients to alleviate symptoms, but their efficacy was variable, partial and/or transitory. The most effective therapies were antihistamines, venlafaxine, and mexiletine. Conclusions: The diagnosis and treatment of EM remain challenging. Patients with this condition display a wide spectrum of clinical manifestations and severity, as well as a paucity of resources and structures to support them. Mutations in the SCN9A gene are not always detected.

show abstract

Alleviation of Erythromelalgia With Venlafaxine

Abstract: is a rare chronic pain disorder. Little is known regarding the pathogenesis of the pain. In this case we discuss the pain management of an adolescent female with EM refractory to medical management.

Cited by 13 publications

References 5 publications

Erythromelalgia

Erythromelalgia

Pain management in children with erythromelalgia: case report

Clinical Challenges in Primary Erythromelalgia: A Real-Life Experience from a Single Center and a Diagnostic-Therapeutic Flow-Chart Proposal

Contact Info

Product

Resources

About